| Literature DB >> 30029002 |
Stephanie Santarriaga1, Holly N Haver1, Adam J Kanack1, Alicia S Fikejs1, Samantha L Sison2, John M Egner1, Jonathan R Bostrom2, Emily R Seminary2, R Blake Hill1, Brian A Link2, Allison D Ebert2, K Matthew Scaglione3.
Abstract
The polyglutamine (polyQ) diseases are a group of nine neurodegenerative diseases caused by the expansion of a polyQ tract that results in protein aggregation. Unlike other model organisms, Dictyostelium discoideum is a proteostatic outlier, naturally encoding long polyQ tracts yet resistant to polyQ aggregation. Here we identify serine-rich chaperone protein 1 (SRCP1) as a molecular chaperone that is necessary and sufficient to suppress polyQ aggregation. SRCP1 inhibits aggregation of polyQ-expanded proteins, allowing for their degradation via the proteasome, where SRCP1 is also degraded. SRCP1's C-terminal domain is essential for its activity in cells, and peptides that mimic this domain suppress polyQ aggregation in vitro. Together our results identify a novel type of molecular chaperone and reveal how nature has dealt with the problem of polyQ aggregation.Entities:
Keywords: Dictyostelium discoideum; Huntington's disease; amyloid; chaperone; polyglutamine; proteasome; ubiquitin
Mesh:
Substances:
Year: 2018 PMID: 30029002 PMCID: PMC6091221 DOI: 10.1016/j.molcel.2018.07.008
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970